• November 6, 2020  

    What’s New in Treatments that Target the MAPK Pathway in Cancer?

    Emma Shtivelman, PhD

    If you are learning about treatment options for your or your loved one’s cancer, you may have heard of the MAPK pathway. This biological feature of human cells has become an important target of numerous drugs to treat cancer. Read on to learn more about the MAPK pathway and the current status of treatments that target it. What is the MAPK pathway? The mitogen-activated… Read more »

  • October 28, 2020  

    Pancreatic Cancer: Why Diet Is Important

    H. Sofia Pereira, PhD

    Pancreatic cancer and nutrition are closely intertwined. Research has shown that diet can help many patients manage the loss of appetite and weight loss that often accompany pancreatic cancer, and good nutrition is linked to better treatment outcomes. Intriguingly, mounting evidence also suggests that specific diets may directly affect the underlying biology of pancreatic tumors and improve the success of pancreatic cancer treatment. Read… Read more »

  • October 26, 2020  

    How an Expert Would Manage His Own Stage 4 Pancreatic Cancer

    With: John Strickler, MD

    When confronted with a new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks Cancer Commons Expert Physician Advisor John Strickler, MD, how he would handle his own diagnosis of metastatic pancreatic cancer. Dr. Strickler is Associate Professor of Medicine in the Division of Medical Oncology at Duke University and Co-Leader of… Read more »

  • October 22, 2020  

    ESMO 2019: Immunotherapy in Cervical and Endometrial Cancers Bookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Contributing Editor George Lundberg, MD, who notes: 

    Recent clinical trial results show that immunotherapy—a type of treatment that boosts the immune system to fight cancer—provided long-lasting, improved outcomes for patients with advanced cervical or endometrial cancer. These are important findings for difficult-to-treat cancers.

    .

  • October 22, 2020  

    Malignant Melanoma Treatment & Management Bookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    The dramatic array of treatment options now available for this serious disease is nicely summarized in this review. (Free registration required, written with a physician audience in mind.)

    .

  • October 22, 2020  

    Cervical Cancer—An Overview Bookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD.

    Cervical cancer can be detected early, but when it is fully developed it requires advanced treatment approaches. This comprehensive review outlines treatment options. (Free registration required, written with a physician audience in mind.)

    .

  • October 16, 2020  

    Lymphoblastic Lymphoma—An Overview Bookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    This 2019 comprehensive presentation of lymphoblastic (precursor B-cell and T-cell) lymphoma emphasizes lymph node-predominant involvement in this blood-lymph node diaspora. (Free registration required, written with a physician audience in mind.)

    .

  • October 16, 2020  

    Hodgkin Lymphoma—An Overview Bookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    This 2020 encyclopedic approach to a potentially curable form of lymphoma is richly detailed and specific for all types and stages of Hodgkin lymphoma. (Free registration required, written with a physician audience in mind.)

    .

  • October 10, 2020  

    Novel Developments in the Multimodality Treatment of Esophageal Cancer Bookmark

    George Lundberg, MD

    A special issue of the research journal Annals of Esophagus curated by Contributing Editor George Lundberg, MD.

    This special issue of an academic research journal discusses “multimodality” treatment—the combination of more than one treatment—and how it is used to treat advanced esophageal cancer.

    .

  • October 8, 2020  

    First Approval of Second-Line Therapy for DLBCL Bookmark

    George Lundberg, MD

    Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

    The FDA has granted accelerated approval to tafasitamab (brand name Monjuvi) as a second-line therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), based upon overall responses seen in a clinical trial. This is the first FDA approval of a second-line treatment for this condition. There are few, if any, other options.

    .